IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin by Saul, Louise et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/srep29736
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Saul, L., Ilieva, K. M., Bax, H. J., Karagiannis, P., Correa, I., Rodriguez-Hernandez, I., ... Karagiannis, S. N.
(2016). IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Scientific
Reports, 6, [29736]. 10.1038/srep29736
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
1Scientific RepoRts | 6:29736 | DOI: 10.1038/srep29736
www.nature.com/scientificreports
IgG subclass switching and clonal 
expansion in cutaneous melanoma 
and normal skin
Louise Saul1,2,*, Kristina M. Ilieva1,3,*, Heather J. Bax1,2, Panagiotis Karagiannis1, 
Isabel Correa1, Irene Rodriguez-Hernandez4, Debra H. Josephs1,2, Isabella Tosi1, 
Isioma U. Egbuniwe1, Sara Lombardi1,5, Silvia Crescioli1, Carl Hobbs6, Federica Villanova1, 
Anthony Cheung1,3, Jenny L. C. Geh7, Ciaran Healy7, Mark Harries8, Victoria Sanz-Moreno4, 
David J. Fear9, James F. Spicer2, Katie E. Lacy1,5, Frank O. Nestle1 & Sophia N. Karagiannis1
B cells participate in immune surveillance in human circulation and tissues, including tumors such as 
melanoma. By contrast, the role of humoral responses in cutaneous immunity is underappreciated. 
We report circulating skin-homing CD22+CLA+B cells in healthy volunteers and melanoma patients 
(n = 73) and CD22+ cells in melanoma and normal skin samples (n = 189). Normal and malignant 
skin featured mature IgG and CD22 mRNA, alongside mRNA for the transiently-expressed enzyme 
Activation-induced cytidine Deaminase (AID). Gene expression analyses of publically-available data 
(n = 234 GEO, n = 384 TCGA) confirmed heightened humoral responses (CD20, CD22, AID) in melanoma. 
Analyses of 51 melanoma-associated and 29 normal skin-derived IgG sequence repertoires revealed 
lower IgG1/IgGtotal representation compared with antibodies from circulating B cells. Consistent 
with AID, comparable somatic hypermutation frequencies and class-switching indicated affinity-
matured antibodies in normal and malignant skin. A melanoma-associated antibody subset featured 
shorter complementarity-determining (CDR3) regions relative to those from circulating B cells. Clonal 
amplification in melanoma-associated antibodies and homology modeling indicated differential 
potential antigen recognition profiles between normal skin and melanoma sequences, suggesting 
distinct antibody repertoires. Evidence for IgG-expressing B cells, class switching and antibody 
maturation in normal and malignant skin and clonally-expanded antibodies in melanoma, support the 
involvement of mature B cells in cutaneous immunity.
Despite being important immune sentinels in inflammation, antigen presentation, and adaptive immunity 
through antibody production, the recruitment and roles of B cells and the humoral immune compartment in 
cancer immune surveillance and in normal tissue homeostasis are insufficiently understood.
B cells that are exposed to antigens in peripheral tissues can undergo clonal expansion and class switching 
to mature antibody classes (IgG1-4, IgA1-2, IgE). Antigen challenge triggers daughter cells to undergo somatic 
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hypermutation (SHM) and to express antibodies with increasing affinity for the specific antigen. Class switch 
recombination (CSR) and SHM, involving the enzyme Activation-induced cytidine Deaminase (AID) can occur 
both in lymph node germinal centers and also in tissues (e.g. lung, nasal mucosa) in response to antigenic chal-
lenge. This provides an enriched antibody repertoire with reactivity and affinity against encountered antigens 
and of different isotypes, conferring the potential to generate antibodies with a variety of Fc-mediated immune 
effector functions1–3.
The presence and nature of skin-resident B cells are ill-defined due to low cutaneous B cell infiltrate numbers. 
Preliminary findings describe a subset of B cells distinct from those in lymph nodes, circulating through sheep 
skin4. Moreover, potential roles for B cells in cutaneous inflammation, allergy and autoimmunity and in skin 
malignancy are reported5–7, suggesting immune surveillance in the context of inflammation or antigenic chal-
lenge in skin. In cutaneous melanomas, IgG-producing B cells may infiltrate tumors and form part of tertiary 
lymphoid structures8,9. Clonal expansion of IgG-expressing clones against tumor-associated antigens has been 
reported to correspond to clinical tumor regression10. Taken together, these studies support potential functions 
for mature humoral responses in normal and inflamed cutaneous sites.
We provide the first report of the human mature skin-resident B cell compartment and its IgG-expressing 
profiles in cutaneous melanoma and in normal skin. We describe evidence for the presence of cutaneous mature B 
cells, distinct IgG subclass distribution profiles, clonal expansion, somatic hypermutation in the IgG heavy chain 
variable regions, and predicted antigen binding site characteristics of the mature humoral response repertoire in 
cutaneous malignant melanoma lesions and in normal skin.
Results
B cells are present in melanoma lesions and normal skin. We aimed to investigate B cell surveil-
lance in cutaneous sites. We found that a small proportion of circulating CD45+CD3-CD14-CD19+CD22+B 
cells in healthy volunteers (n = 24) and patients with melanoma (n = 49) express the skin-homing Cutaneous 
Leucocyte-associated Antigen (CLA) (Fig. 1a, Figure S1a). Immunohistochemical evaluations revealed CD22+ 
cells in normal skins and melanomas (n = 189, Fig. 1b, Figure S1b). We detected low frequencies of CD22+ 
infiltrates in 31.3% of normal skin samples (n = 16). CD22+ infiltrates were found in 37.6% of melanomas (27% 
cutaneous lesions, 49.1% lymph node metastases, 38% distant metastases), with ~10% of melanomas featuring 
denser B cell infiltrating populations (>10 cells per high powered field, Fig. 1b,c). Cutaneous B cell infiltrates 
from non-malignant skin and melanoma lesion samples were also confirmed by flow cytometric analyses of 
CD45+CD19+CD22+B cells (Fig. 1d, for matched normal skin and melanoma lesion B cells and peripheral 
blood B cells from a single donor, representative of n = 4; Figure S2 for further examples of CD45+CD19+B cells 
from normal skin and melanoma lesion samples).
Analysis of publicly-available gene expression data extracted from human melanoma samples derived from 
Gene Expression Omnibus (GEO)11–13 further supports the expression of the genes for B cell markers MS4A1 
(CD20) and CD22 and of the transiently-expressed SHM/CSR enzyme AICDA (AID) in normal skin, primary, 
and metastatic melanomas. All three B cell markers were upregulated in melanoma compared with normal skin 
samples and in metastatic compared with primary melanomas (n = 234, GEO database) (Fig. 2a). Increased rel-
ative expression of CD20, CD22 and AID in metastatic compared with primary melanoma were also found by 
analyses of the Cancer Genome Atlas (TCGA) database (Fig. 2b). Furthermore, a significant association between 
higher CD20 mRNA expression (p < 0.001) with longer patient survival (TCGA, n = 384, Fig. 2c) was observed, 
consistent with previous studies14–16.
Thus, B cells may be recruited to normal skin and cutaneous melanoma sites, based on expression of the 
humoral immune cell markers CD20, CD22 and AID.
Biased IgG subclass distribution and antibody complementarity-determining region 3 (CDR3) 
lengths in cutaneous sites compared with IgG from circulating B cells. To determine the subclass 
distribution and heavy chain variable region profiles of antibodies expressed at cutaneous sites in our sample 
collection, we identified n = 51 unique mature IgG sequences from 9 cutaneous melanoma samples (patient char-
acteristics in Table S1) and n = 29 unique mature IgG sequences from 13 normal skin samples.
Samples with detectable IgG mRNA (Fig. 3a), expressed CD22 and some specimens from both groups also 
had detectable mRNA for the enzyme AID (Figs 3b and S3), suggesting the presence of a local cutaneous B cell 
and humoral response irrespective of malignant disease status.
We previously reported that B cells in melanoma feature distribution of IgG subclasses with lower representa-
tion of IgG1/IgGtotal (40–45%) and proportionally-higher levels of IgG4/IgGtotal (~20%) than those in human adult 
circulation at the protein level (65–80% IgG1, 2–4% IgG4)8,17,18. We examined 51 unique mature IgG sequences 
from 9 cutaneous melanoma samples, 29 unique mature IgG sequences from 13 normal skin samples and 36 
unique mature IgG sequences randomly derived from circulating B cells of 12 patients with melanoma. From the 
molecular profiles of the mature IgG subclasses, 34% of the sequences detected from melanoma samples were 
IgG1, and 12% belonged to the IgG4 subclass (Fig. 3c). Normal skin samples displayed a similar distribution pat-
tern, with lower representation of IgG1/IgGtotal sequences (24%) (Fig. 3c, Table S2). These profiles were distinctly 
different to the IgG sequences (n = 36) from circulating B cells of patients with melanoma, in which IgG1 was 
the predominant subclass (62% IgG1). These findings indicate that B cell IgG subclass profiles in cutaneous sites 
feature a lower representation of IgG1 antibodies compared with those from B cells in the circulation.
In the same sample cohort (51 mature IgG sequences from cutaneous melanomas, 29 IgG sequences from 
normal skins and 36 IgG sequences from circulating B cells of patients), the sequences derived from cutaneous 
melanoma lesion B cells featured representation of immunoglobulin variable heavy chain region (IgVH) families 
(VH1-5), with highest representation from VH3 (36%) and VH5 (431) (Fig. 3d). IgG sequences from normal 
skins also showed only VH3 (78%) and VH5 (22%) family usage. The predominant families in circulating B cell 
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Figure 1. B cells may be recruited to skin and are present in melanoma lesions and normal skins.  
(a) Proportion (%) of circulating B cells positive for the skin homing marker CLA from patients with 
melanoma (n = 49) and healthy volunteers (n = 24), quantified by multi-color flow cytometric evaluations. 
Peripheral blood B cells were identified as CD3-CD14-CD19+CCD22+ cells (top panel). Representative dot 
plots of CLA+CD45+B cells from a melanoma patient and a healthy volunteer are shown (bottom panel). 
Quantification was based on % CLA+B cells from CD45+CD3-CD14-CD19+CCD22+PBMCs (right panel). 
(b) CD22+ cells in normal skin (left), cutaneous melanoma lesions (middle) and lymph node metastases (right) 
were detected by immunohistochemistry (tissue microarrays, top/bottom: example images per cohort, acquired 
on a Leica AxioScan, 40x objective; Scale bars: 66 μm). (c) CD22+ cell infiltrates per high-powered field (HPF) 
were quantified; Top panel: n = 189 melanomas, n = 16 normal skin samples; Bottom panel: CD22+ infiltrates 
stratified into cutaneous, lymph node and distant metastases. (d) B cells were detected from peripheral blood, 
melanoma lesion and normal skin samples using antibodies against CD19+, CD22+ (both FITC) and CD45+ 
(PE) and analysed by flow cytometry (example from matched blood, normal skin and cutaneous melanoma 
samples derived from a patient with melanoma).
www.nature.com/scientificreports/
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sequences are VH3 (55%) and VH4 (16%). A closer inspection of the VH, VD and VJ gene segment usage showed 
a broad use of VH, VD, and VJ genes in patient circulating B cells. In sequences from B cells in melanoma lesions 
and healthy skin, we detected a preference for the usage of specific gene segments (red arrows, Figure S4), possibly 
suggesting a tissue-resident humoral compartment.
We then explored the lengths of the complementarity-determining CDR3 regions (IMGT/V-quest), the hyper-
variable areas largely responsible for determining antibody binding specificity and affinity to cognate antigens19. 
We found a double-peak distribution of CDR3 lengths in sequences from melanoma lesions (Fig. 3e), which 
suggests that these sequences are not sampled from a Gaussian distribution (p = 0.0073, D’Agostino-Pearson 
test) and that the melanoma-derived sequences appear to feature a group with shorter hypervariable regions than 
those found in blood.
This may suggest the rise of a specific group of B cell clones in malignant skin when compared to healthy vol-
unteer skin and circulating B cells from melanoma patients20.
IgVH sequences from melanoma and normal skins display comparable rates of mutation and 
clonal selection profiles. To assess the maturation state of the IgG antibodies expressed at cutaneous sites, 
we measured the silent and non-silent mutations which result in divergence from respective germline sequences.
We found comparable mutagenic rates in melanoma and normal skin antibodies, suggesting similar levels of 
affinity maturation (Fig. 4a, Mann-Whitney test). Since affinity maturation and local clonal expansion may also 
be associated with negative clonal selection (editing)21, we quantified positive or negative selection of B cells by 
comparison of sequences to reference germline sequences using the BASELINe server. This determines the rate 
of mutation in specific areas of the VH sequence and therefore the survival and persistence of specific IgG VH 
sequence-expressing B cells in situ22. In the CDR regions (Fig. 4b), 63% of sequences from melanoma lesions and 
63% from normal skin samples and in the framework regions (FWR) (Fig. 4c), 90% of sequences from melano-
mas and 76% from normal skin samples, were predicted to be undergoing negative selection (Figure S5).
Together, these suggest that the rates of mutation, and by extension, the maturation of the antibody variable 
region sequences, in normal skins and melanoma lesions appear comparable.
Cutaneous melanoma- and normal skin-derived sequences display similar somatic hypermu-
tation hotspot patterns, but distinct predicted binding sites. We examined the amino acid residue 
Figure 2. Upregulation of B cell markers in primary and metastatic melanomas compared with normal 
skins by gene expression analysis. (a) The relative expression of genes for the humoral immune markers CD20, 
CD22 and AID are elevated in primary and metastatic lesions compared with normal skin samples and also 
elevated in metastatic versus primary melanomas (n = 234, normalized microarray gene expression data from 
indicated studies, GEO database; One-way ANOVA with Tukey’s post hoc test). (b) Increased CD20, CD22, 
and AID relative expression in primary versus metastatic melanomas (n = 384, TCGA database; T-test with 
Welch’s correction was performed). (a,b) Graphs show mean ± SEM gene expression, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. (c) Kaplan-Meier estimates of overall survival in TCGA melanoma patients 
according to CD20, CD22 and AID mRNA expression. Gene expression was categorized as low and high 
expression according to the median expression value and differences were compared using the log-rank test. 
High CD20 expression was significantly associated with better survival (n = 384; Hazard ratio (HR):1.82; 95% 
confidence interval (CI):1.36–2.43; p < 0.001). Detailed statistical analyses are described in Materials and 
Methods.
www.nature.com/scientificreports/
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positions at which cumulative divergence from the germline occurred (incidence of non-silent mutation in 
>35% of sequences; threshold indicated by horizontal lines)23 (Fig. 5a,b). High densities of mutations from both 
cohorts cluster in areas bordering FWR1/CDR1, FWR2/CDR2, CDR2/FWR3 and in FR3 (red boxes). This signi-
fies somatic hypermutation, supported by clonally-expanded sequences in melanoma and normal skin samples, 
featuring point mutation divergence from the germline (red) (Figure S6).
Furthermore, we examined individual residues predicted to be involved in antigen recognition (i-Tasser)24. We 
observed a higher concordance (overlap) between the rates of somatic hypermutation (black) and the predicted 
areas of antigen binding (red) in the melanoma-derived sequences, compared with overlap between somatic 
Figure 3. IgGVH, CD22, AID in human skin, IgG subclass and hypervariable region analyses support 
unique cutaneous IgG subclass and CDR3 length profiles. (a) IgGVH regions were amplified and mature  
IgG mRNA (red stars) detected. (b) In these samples, CD22 mRNA was detectable (qPCR) in melanoma  
lesion (black) and normal skin (grey) samples (black asterisks indicate samples expressing AID mRNA).  
(c,d) IgG subclass and VH family usage represented as the frequency from the total number of sequences 
(n = 51 cutaneous melanoma, n = 29 normal skin, n = 38 circulating B cell sequences, human BLAST) reveal 
specific cutaneous versus circulating IgG subclass profiles. (e) CDR3 hypervariable region analyses from 
melanoma lesions (n = 51, red), normal skins (n = 29, blue), melanoma patient circulating B cells (n = 38, black) 
(IMGT/V-quest database) suggest differential CDR3 length distribution in melanoma.
www.nature.com/scientificreports/
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hypermutation frequency (black) and predicted binding residues (blue) in normal skin-derived sequences 
(Fig. 5c,d, left).
We then constructed homology models of the VH immunoglobulin fold, to highlight the residues predicted 
to likely be involved in antigen binding in >25% of the sequences from each cohort (above horizontal lines, 
Fig. 5c,d, left). These revealed different predicted areas of potential antigenic binding in melanoma-derived com-
pared with normal skin-derived sequences (Fig. 5c,d, right). A single region of potential antigen binding was pre-
dicted in the 51 sequences from melanoma lesions, while several dispersed clusters of binding sites were predicted 
in normal skin sequences laid over the predicted variable region fold.
These data may indicate that different areas of the VH regions of tissue-resident B cell-derived antibodies from 
the two cohorts of melanoma and normal skin samples participate in F(ab) mediated binding.
Evidence for antibody class switch recombination in melanomas and normal skin and clonal 
expansion in melanomas. Expression of B cell markers, IgG subclasses and AID (Figs 1–3) at cutaneous 
sites, along with indications of negative clonal selection and variable region mutation hotpots (Figs 4 and 5) may 
signify local class switching to different IgG subclasses and B cell clonal expansion in skin. Consistent with this, 
in each cohort of melanoma and normal skin samples we found antibodies displaying identical V(D)J sequences 
that belonged to different subclasses (Fig. 6a). Taken together with the presence of AID, these findings may sug-
gest in situ cutaneous class-switch recombination. Additionally, clonally-related sequences of separate IgG sub-
classes determined by identical V(D)J germline ‘parent’ clones were detected only in melanoma samples (three of 
nine samples) (Fig. 6b). B cell clonal family trees from 3 melanoma samples confirmed melanoma-resident clonal 
expansion and clonally-related sequences with point mutations at more than one residue (Fig. 6c); furthermore 
we also found in one of these families that there was antibody subclass switching alongside clonal expansion.
Figure 4. Similar mutational rates and clonal selection in melanoma and normal skin IgG antibodies.  
(a) Silent and non-silent mutations in the IgG VH regions determined using IMGT V-quest. Healthy volunteer 
skin (grey) and melanoma (black) samples show no significant differences in the antibody mutational rates. 
(b&c) Quantified clonal selection in the CDR (b) and FWR (c) regions from IgG VH sequences for each 
melanoma (red symbols ± SEM) and normal skin (blue symbols ± SEM) samples. NS: not significant. Please see 
Supplementary Materials and Methods (each symbol represents the mean value of selection from the sequences 
from each individual donor).
www.nature.com/scientificreports/
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Together, these indicate active class switch recombination (CSR) to different IgG subclasses in normal and 
malignant cutaneous sites, alongside B cell clonal expansion in melanoma lesions only, pointing to humoral 
responses against local immune and inflammatory signals or antigenic challenge.
Discussion
We present evidence supporting the presence of mature, skin-resident IgG antibody-expressing B cells. Our find-
ings add to previous reports of IgG-expressing B cells in melanoma lesions, B cells from patients that express anti-
bodies reactive to tumor cells, and dysregulated levels of IgG subclasses in melanoma lesions and patient sera14,16.
Despite previously-reported positive associations between tumor-associated B cells and better clinical prog-
nosis in melanoma15,25–27, here supported by our TCGA database gene expression analyses, the recruitment and 
roles of B cells and especially of the mature cutaneous humoral immunity remain insufficiently uncharacterized. 
Therefore, in our study we focused on analyzing B cells, the transiently-expressed class switch recombination 
and somatic hypermutation enzyme AID and mature IgG antibody sequences from cutaneous B cells in order to 
evaluate maturation and isotypes of locally-expressed antibodies.
Figure 5. Somatic hypermutation frequency hotspots and predicted binding sites define distinct patterns 
in cutaneous melanomas and in normal skins. Divergence from germline sequences from melanomas 
(a), (n = 51) and normal skins (b) (n = 29) (red boxes: mutational clusters) (horizontal lines ≥ 35% identify 
somatic hypermutation ‘hotspots’). ((c,d), Left) Frequency of occurrence of predicted binding residues (n = 51 
melanomas, red (c)), (n = 29 normal skins, blue (d), clusters indicated by arrows), superimposed on somatic 
hypermutation frequencies (black). Sequences compared to IMGT for non-silent mutations resulting in amino 
acid change; FWR and CDR: vertical dotted lines; horizontal lines at ≥25% identify predicted binding sites. 
((c,d), Right) Residues predicted to participate in antigen recognition in ≥25% of sequences (red, melanomas; 
blue, normal skins) on a homology model of a V region sequence.
www.nature.com/scientificreports/
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Subsets of circulating (CD22+) B cells in patients with melanoma and healthy volunteers harbor skin hom-
ing potential, based on expression of CLA28. In concordance, we detected cutaneous B cells by flow cytome-
try, immunohistochemistry and qPCR. Mature IgG mRNA in skin and skin tumor lesions and mRNA for the 
transiently-expressed SHM/CSR enzyme, AID, point to a mature activated cutaneous humoral immune compart-
ment with respect to antibody affinity maturation and class switching potential.
Humoral immunity can mount antibody responses through recognition of upregulated cancer-associated 
antigens, but conversely, cross-talk with tumors may educate these responses to adopt regulatory functions29. 
This may be manifested by tumor states supporting expression of regulatory antibody subclasses such as IgG4, 
normally associated with inflammation or immune regulation30–32. In line with this and with our previous find-
ings at the protein level, we confirmed that melanoma-associated IgG subclass expression distribution lacks a 
predominant IgG1 representation and instead features proportionally-higher regulatory subclass IgG4 sequences 
(~20% IgG4/IgGtotal). Surprisingly, we detected a lower than expected proportional IgG1/IgGtotal expression pro-
file in normal skin samples. Dysregulated levels of IgG4 were also expressed by patient blood B cells, consistent 
with previous reported findings33. These are in contrast to well-documented IgG subclass representation in nor-
mal adult circulating and lymph node-resident B cells, where IgG1 is the predominant subclass (65–80% IgG1, 
2–4% IgG4)17,18.
The presence of a skin-resident IgG-expressing cutaneous humoral compartment is not entirely unexpected. 
B cells are reported in autoimmune conditions with cutaneous pathogenic manifestations such as Pemphigus 
vulgaris, where B cells and auto-reactive antibodies are detected in skin and systemically, contributing to disease 
pathology34. IgG4 is implicated in autoimmune and inflammatory cutaneous diseases, including Pemphigus vul-
garis, where deposits of IgG4 (and IgE) auto-antibodies home in to skin lesions. IgG2, which we also detected 
in our skin cohorts, is normally associated with responses to bacterial antigens, to which the skin may be com-
monly exposed35–40. These skin-resident IgG subclass profiles without a predominant IgG1 representation may 
therefore be consistent with a role for B cells in maintaining local homeostasis, and responding to local pathogen 
challenge41,42.
We observed an active B cell compartment in melanoma lesions, supported by different findings and these, 
along with gene expression analyses of published data, implicate tissue-resident B cells and AID expression in 
primary and in metastatic melanomas. A subset of melanoma-resident and perhaps skin-resident B cell clones 
displayed different CDR3 lengths when compared with those from the circulation, indicating humoral immune 
responses focused towards a specific antigenic stimulus. Consistent with antigen-focused clonal expansion, 
homology modeling of melanoma-derived antibodies suggested structural clustering of amino acid residues 
highly predicted to be involved in binding. This may indicate antibody maturation under clonal selection pressure 
in melanoma. Furthermore, we found active class switching in identical B cells in normal and in malignant cuta-
neous sites. Importantly, we found class switching in clonally-related B cells and clonal family trees in melanomas 
but not in normal skin samples, possibly associated with responses to tumor antigens and tumor evolution43,44. 
Therefore, the combination of affinity maturation, class switch recombination and clonal expansion might be a 
Figure 6. Cutaneous class-switched B cells in normal and melanoma skins and melanoma-associated 
clonally-expanded B cells. Number of V-D-J germline sequences displaying clonal expansion (IMGT V-quest) 
and switching to different IgG subclasses (human BLAST). (a) Class switching of identical V(D)J sequences 
from melanoma lesions (n = 6) and normal skins (n = 3) to different IgG subclasses. (b) Class switching of 
clonally-related amino acid sequences (n = 3), determined by identical V(D)J germline \‘mother\’ clones 
in the melanoma cohort only. (c) Clonal family trees constructed from melanoma lesion sequences display 
expansion from the same germline sequences. Germline indicated in rectangular boxes; circles with numbers 
indicate arbitrary number given to sequence; circles labeled ‘x’ represent hypothetical progenitor daughter cells; 
numbers next to clones indicate V-region amino acid positions where mutations are detected.
www.nature.com/scientificreports/
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feature of melanoma-associated antibodies, consistent with active and heightened humoral responses to a specific 
antigen repertoire45.
In summary, we report basal levels of a mature humoral immune response in normal skins and an enhanced B 
cell clonal presence in cutaneous melanomas. Skin tumor-associated B cell receptor repertoires and IgG subclass 
profiles point to an active tumor-infiltrating B cell compartment with features distinct to those of circulating B 
cells. Our findings of local B cell clonal expansion, antibody affinity maturation and predicted antigenic binding 
patterns on antibody variable regions also raise the possibility that a heightened mature IgG antibody response in 
melanoma may be edited towards specific antigen stimuli. Melanoma may activate but also pervert skin-resident 
humoral immune response homeostasis to control activated, mature B cell responses. This may be through main-
taining skin-resident antibody subclass distribution featuring immune regulatory subclass antibodies such as 
IgG4, as a mechanism of evading immune surveillance.
Our data thus report a humoral response in skin immune surveillance and homeostasis and support expanded 
tumor-associated humoral immunity in cutaneous melanoma. These findings mandate a closer study of the cuta-
neous humoral immune cell compartments to elucidate the involvement of B cells and locally-expressed antibod-
ies in skin immune surveillance and their roles in melanoma tumor pathology.
Materials and Methods
Sample collection and characterization of human B cells. Patients with malignant melanoma were 
staged and classified according to the American Joint Committee on Cancer Melanoma Staging and Classification 
criteria46. Discarded human skin samples were obtained from volunteers undergoing routine plastic surgery. 
Specimens were collected with informed consent in accordance with the Helsinki Declaration (approved by the 
Guy’s Research Ethics Committee, Guy’s and St. Thomas’ NHS Foundation Trust). Samples were used freshly or 
placed in RNAlater (Life Technologies) and stored at −70 °C.
For evaluations of CLA+B cells, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque 
Plus density centrifugation GE Healthcare). Cells were resuspended in RPMI 1640 medium (Life Technologies) 
11.25% human serum albumin (Gemini Bio-Products, West Sacramento, CA), 10% DMSO (Sigma) and stored in 
liquid nitrogen. For analyses, cells were thawed, selected based on SSC-A/FSC-A properties, dead cells excluded 
using LIVE/DEAD® Fixable Dead Cell Stains in Qdot585 (Life Technologies) and single cells selected by FSC-A/
FCS-H. Cells were incubated with antibodies for the following surface markers (BD Biosciences): CD45(V500), 
CD22 (APC), CD19 (BV605), CD3 (APC-Cy7), CD14 (Alexa Fluor 700) and CLA (FITC). Samples were subse-
quently acquired on a 5-laser SORP Fortessa (BD Bioscience) and data analyzed using FlowJo software (Treestar).
Single cell suspensions from normal skin and cutaneous melanoma samples were obtained by mild physical 
dissociation (Gentle MACS, Miltenyi Biotec). Cells were allowed to crawl out from tissues overnight in RPMI 
1640 medium, 10% FCS, at 37 °C, 5% CO2. Tissues were filtered through a 100 μm strainer. B lymphocytes were 
also identified from matched peripheral blood samples after Ficoll-Paque (GE Healthcare) gradient centrifuga-
tion. Cells were treated with FcR Blocking Reagent (Miltenyi Biotec), selected based on SSC-A/FSC-A properties, 
DAPI to exclude dead cells and labeled with anti-human antibodies to the following markers: CD19 (FITC), 
CD22 (FITC), CD45 (PE) or with CD19 (FITC) and CD45 (PerCP) (BD Biosciences) to detect B cells by flow 
cytometry (FACSCanto, BD Biosciences). Data were analyzed using FlowJo software (Treestar).
Immunohistochemical evaluations of CD22+ cells. To detect CD22 expression, 6–8 μM-thick mela-
noma tissue microarray (ME2802, US Biomax) samples were de-paraffinized in xylene before rehydration. Heat 
antigen retrieval and staining with mouse anti-human CD22 (Abcam) were followed by biotinylated goat/rabbit 
anti-mouse IgG (DAKO) and detection using Vector red alkaline phosphatase substrate with levamisole (Vector 
labs). Images were acquired using ZeissAxioScan microscope with 40x objective and Olympus Provis stereology 
microscope with 40x planapo objective, and analyzed using the Zen Blue software (Leica).
RNA extraction and cDNA synthesis to identify IgG-expressing cutaneous specimens. Tissues 
stored in RNAlater were thawed at room temperature, homogenized in RLT buffer (RNeasy kit, QIAgen) using 
a Kinematica Polytron homogenizer (Fischer Scientific). RNA was extracted using the RNeasy kit (QIAgen) and 
quantified using a Nanodrop spectrophotometer (Thermo Scientific). 500 ng RNA was used to synthesize cDNA 
using SuperScript ® II reverse transcriptase (Life Technologies). RNA extracted from 27 normal skin and 21 mel-
anoma samples yielded n = 29 IgG sequences from 13 normal skins and n = 51 IgG sequences from 9 melanoma 
samples; RNA from n = 36 single B cell IgG sequences was obtained from PBMC samples of 12 patients with 
melanoma using a single cell lysis kit (Ambion, ThermoFisher) following manufacturer recommendations. cDNA 
synthesis was conducted using the SuperScript VILO cDNA Synthesis kit (Invitrogen, ThermoFisher).
Quantitative PCR analysis of cell marker expression. cDNA was synthesized and used in conjunction 
with a FAM-labelled Taqman gene expression kit for human CD22 (Hs00998488) and AID (Hs00757808), with 
VIC-labeled β2-microglobulin as endogenous control (Life Technologies); 384-well plates were used with the 
7900HT system (Applied Biosystems) to amplify CD22 and AID. Endogenous control and mRNA abundance 
were normalized against human β2-microglobulin mRNA (VIC) (2ΔCt). AID expression was normalized against 
CD22 mRNA (VIC) (2ΔCt).
Semi-Nested PCR to amplify VH-Cγ transcripts and sequencing VH regions. Amplification of 
VH-Cγ transcripts consisted of 2 rounds of semi-nested PCR: 1st reaction used 2 μL of the cDNA and 6 leader 
sequence PCR forward primers (VH1L-VH6L), along with an IgGPr reverse primer at 0.5 μM in a PCR reaction 
with high fidelity polymerase master mix Phusion Flash (Thermo Scientific) (Table S3); 2nd reaction proceeded 
with Phusion Flash mix using 2 μL of the first reaction with class-specific PCR forward primers (VH1F-VH6F) 
and the same IgGPr reverse primer as in 1st reaction (at 0.5 μM). VH-Cγ transcripts were identified by (1%) 
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agarose gel electrophoresis (650 bp). Fragments were isolated by band excision and DNA extraction (QIAgen gel 
extraction kit, QIAgen). DNA was cloned by blunt-ended ligation into pCR-Blunt from the Zero Blunt® clon-
ing kit (Life Technologies). Ligation reactions were transformed into chemically-competent E. coli OneShot™ 
TOP10 cells (Life Technologies). Colonies were selected and treated for pCR-Blunt plasmid extraction (QIAgen 
plasmid miniprep kit). Plasmids were sequenced using the M13 forward and reverse sequencing primers (Source 
Bioscience) (Table S4).
IgG sequence analyses. Cloned IgG V-region sequences were obtained from sequence reactions using the 
FinchTV software (PerkinElmer). Forward and reverse IgG sequences were analyzed using IMGT/V-Quest to 
determine IgG heavy chain family, V-D-J germline, and hypermutation sites47. Selectivity of the cloned V-regions 
was determined using the BASELINe server according to the IMGT numbering strategy22, http://selection.med.
yale.edu/baseline/).The Baseline server compares expected versus observed rates of mutation to quantify selective 
pressure; a binomial test is used to quantify statistical significance. IgG subclass was determined by comparing the 
reverse IgG variable region sequence in the NCBI database using human BLAST48; alignments displaying highest 
identity with greatest coverage and ≥90% sequence match to a specific subclass and following confirmation with 
described subclass amino acid patterns were included49. Amino acid sequences of isolated V-D-J regions were 
summed across all sequences for each cohort and plotted according to residue number and submitted in entirety 
to the i-Tasser database to evaluate structure and areas of predicted binding 24.
Analysis of B cell marker gene expression from human databases. Publicly-available data from 
n = 234 human skin and melanoma samples were extracted from the Gene Expression Omnibus (GEO) data-
base (GSE7553, n = 58)12; (GSE46517, n = 93)11; (GSE8401, n = 83)13. Data were normalized using Gene Pattern 
software50.
Gene expression data of n = 384 human melanoma samples from The Cancer Genome Atlas (TCGA) database 
(http://cancergenome.nih.gov/) were also used to analyze CD20, CD22 and AID mRNA expression in mela-
noma progression. We only considered samples from patients who had not received neo-adjuvant treatment prior 
to tumor resection for the sample submitted for TCGA. Normalized mRNA expression data were downloaded 
from cBioPortal51. Gene expression data analyses were presented as mean ± standard error of the mean (SEM). 
Statistical analyses are described below.
Statistical analyses. GraphPad Prism software (GraphPad Software, www.graphpad.com) was used for 
statistical analyses (One-way ANOVA with Tukey’s post hoc test and T-test with Welch’s correction for deter-
mination of relative gene expression of GEO database and of TCGA database respectively; Mann-Whitney test 
for B cell distribution and analysis of associated markers with cancer progression; ANOVA to determine differ-
ences in mutational rates; Kolmogorov-Smirnov goodness-of-fit; D’Agostino & Pearson normality test to analyze 
CDR3 length distribution). For survival analyses, mRNA expression data from TCGA samples were categorized 
as low expression and high expression using the median expression as cut-off. Kaplan Meier survival curves were 
compared among patient subsets using the log-rank test. The Hazard Ratio (HR) was calculated using the Cox 
proportional hazard model. Survival analyses were performed using the SPSS software (IBM; http://www-01.ibm.
com/software/uk/analytics/spss/). Differences with P-values < 0.05 were considered statistically significant and all 
tests were two-sided (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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